Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMEL1 | Q495T6 | 11/20 | 0.60 |
| ▸ | MME | P08473 | 8/20 | 0.49 |
| ▸ | ACE | P12821 | 6/20 | 0.47 |
| ▸ | EMG1 | Q92979 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2875342 | 1.00 | MMEL1 (0.60) | MMEL1MMEACEEMG1MAPT | |
| SCHEMBL2870528 | 0.89 | MMEL1 (0.68) | MMEL1MMEACE | |
| SCHEMBL2870535 | 0.89 | MMEL1 (0.68) | MMEL1MMEACE | |
| SCHEMBL12975389 | 0.86 | MMEL1 (0.53) | MMEL1MMEACEEMG1MAPT | |
| SCHEMBL2872629 | 0.85 | MMEL1 (0.67) | MMEL1MMEACEMAPT | |
| SCHEMBL2872628 | 0.85 | MMEL1 (0.67) | MMEL1MMEACEMAPT | |
| SCHEMBL14870603 | 0.85 | MMEL1 (0.54) | MMEL1MMEACEEMG1MAPT | |
| SCHEMBL12975580 | 0.85 | MMEL1 (0.58) | MMEL1MMEACEEMG1 | |
| SCHEMBL2876311 | 0.85 | MMEL1 (0.57) | MMEL1MMEACEMAPT | |
| SCHEMBL2876313 | 0.85 | MMEL1 (0.57) | MMEL1MMEACEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435409-B1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| EP-2435409-B1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| EP-2594556-A1 | Substituted aminopropionic derivatives as neprilysin inhibitors | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-8394853-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | MME, AGTR1, REN | MMEL1 299/4885MME 1/4885ACE 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.